Alkem Laboratories Limited
Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.(Source : 202003-01 Annual Report Page No:107)
What Alkem files
- Others96
- Investor Meet62
- Updates42
- Important22
- Board Meeting11
- PPTs11
Alkem Laboratories Limited has informed the Exchange about Investor Presentation
Alkem Labs reported strong Q4 & FY26 results! 🎉 Q4 revenue jumped 14.6% YoY to ₹3,603.3 Cr. India sales grew 8.8% to ₹2,324.5 Cr, and international sales soared 25.4% to ₹1,222.3 Cr. For FY26, total revenue was up 13.5% YoY at ₹14,712.3 Cr. India sales hit ₹9,851.4 Cr (+9.7%), and...
Alkem Laboratories is making a significant move into the high-growth MedTech sector, projected to reach $870B globally by 2030. Alkem MedTech is prioritizing Musculoskeletal and Cardiovascular segments. Their Musculoskeletal division already shows strong traction with over 50% sequential implant growth and aims for 10% India market share in large joints...
Alkem MedTech is strategically entering the global MedTech market, projected to hit $870 billion by 2030, with India's market growing +13% annually to $30 billion. **Business Performance:** The company is focusing on Musculoskeletal and Cardiovascular segments. Its Musculoskeletal division saw strong performance with over 150 repeat customers and >50% sequential...
Alkem Labs saw robust Q3 FY26 performance with revenue up 10.7% YoY to ₹3,736.8 Cr. India sales grew 5.5% to ₹2,495.9 Cr, outperforming the Indian Pharma Market in key acute and chronic segments. International sales surged 26.6% to ₹1,215.7 Cr, boosted by strong US growth (+18.8% to ₹753.3 Cr) and...